You are here
AstraZeneca shares plunge as the firm's lung cancer study fails
ASTRAZENECA'S combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, sending its shares plunging on Thursday.
The so-called Mystic study was the most anticipated
- CALL +65 6388 3838
- EMAIL email@example.com